Asahi shares mark weekly slide after cyberattack halts production
Eric W. Roberts, Chief Business Officer at CalciMedica, Inc. (NASDAQ:CALC), acquired 2,343 shares of common stock on September 9, 2025, for a total value of $7,377. The shares were purchased at a weighted average price of $3.1488, with individual prices ranging from $2.75 to $3.21. The stock, currently trading at $3.38, has shown strong momentum with a 10% gain in the past week. According to InvestingPro analysis, analysts maintain a strong buy consensus with price targets ranging from $14 to $20.
The transaction increased Roberts’ indirect holdings to 73,250 shares held By FMTC Custodian - Roth IRA FBO Eric W. Roberts. The $47 million market cap company maintains a healthy balance sheet with more cash than debt and a strong current ratio of 5.45. Want deeper insights into insider trading patterns and 10+ additional exclusive ProTips? Check out InvestingPro.
In other recent news, CalciMedica Inc. has published a manuscript in the American Journal of Nephrology detailing the design and rationale for its Phase 2 KOURAGE trial. The trial focuses on Auxora, a treatment for acute kidney injury (AKI) with respiratory failure. The manuscript highlights preclinical data indicating that Auxora significantly increased the glomerular filtration rate in rat models of AKI. Additionally, a post-hoc analysis from the company’s CARDEA trial revealed a 62.7% relative reduction in mortality among COVID-19 patients with AKI who were treated with Auxora compared to those who received a placebo. These developments are part of CalciMedica’s ongoing efforts to advance its research and treatment options in the field of nephrology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.